Why did Amylyx Pharmaceuticals (AMLX) stock rise before market open? - Kalkine Media

September 08, 2022 05:42 AM PDT | By Rupam Roy
Follow us on Google News:

Highlights:

  • The AMLX stock jumped more than 80 per cent in the pre-market trading on Thursday.
  • It returned gains of around 78 per cent in the ongoing year.
  • Amylyx Pharmaceuticals had a market cap of about US$ 1.05 billion.

The stocks of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) seem to be gaining attention on September 8, as seen by the rise in its trading price during the pre-market hours.

The AMLX stock rocketed more than 80 per cent in the pre-market trading session after closing about four per cent higher in the prior session.

Now the question is why the stock witnessed a notable gain on Thursday. Let's discover the recent developments that may have bolstered its gains with Kalkine Media®.

Why is it soaring?

Amylyx Pharmaceuticals gained traction on September 7 after the firm said that Nasdaq had halted the trading of its common stock. During that statement, it also said that the second meeting of the US Food and Drug Administration would happen on the same day for reviewing the New Drug Application for AMX0035, which is used to treat amyotrophic lateral sclerosis (ALS).

Meanwhile, on September 8, the pharmaceutical firm said that the regulators backed its drug at their meeting. The Cambridge, Massachusetts-based firm said that the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) voted on a 7:2 ratio, with the majority backing its efficacy.

Seven advisers have recommended approval for its experimental drug, which may have surprised some investors after the same group turned down the much-debated drug earlier in 2022.

Most of the regulators backed the available data that shows the drug's efficacy to support its approval in treating ALS. Notably, if approved, AMX0035 would be the first treatment for ALS that had shown a notable slowing down in the disease's progress and impact.

The FDA had nodded for Priority Review for AMX0035 in December 2021, and according to the recent statement of the US$ 1.05 billion market cap firm, it anticipates that the regulators would give a decision on the drug by September 29 this year, under Prescription Drug User Fee Act.

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 FY22 VS Q2 FY21 earnings highlightsSource: ©Kalkine Media®; © Canva via Canva.com

Bottom line:

The AMLX stock was priced at US$ 32.23 at 7:53 am ET on September 8, an increase of 80.06 per cent from its previous closing price of US$ 17.90. On September 7, it closed at 4.37 per cent more than its previous close.

During its writing, it had a volume of 757,822. At its current trading price, it returned gains of about 78 per cent YTD while increasing around 66 per cent in the ongoing quarter.

However, the stock of Amylyx Pharmaceuticals had an RSI of about 31, Refinitiv data showed, which suggests that the stock could be highly volatile at the moment.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.



Top Listed Companies